American Century Companies Inc Kinnate Biopharma Inc. Transaction History

American Century Companies Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$1.38 - $3.31 $20,570 - $49,338	14,906 New	14,906 $20,000
Q4 2022 Feb 13, 2023	BUY	$5.26 - $12.19 $1,030 - $2,389	196 Added 0.06%	322,030 $1.96 Million
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $18,526 - $29,613	1,879 Added 0.59%	321,834 $3.85 Million
Q2 2022 Aug 12, 2022	BUY	$7.43 - $13.0 $3,180 - $5,564	428 Added 0.13%	319,955 $4.04 Million
Q1 2022 May 11, 2022	BUY	$7.73 - $17.99 $818,467 - $1.9 Million	105,882 Added 49.56%	319,527 $3.6 Million
Q4 2021 Feb 07, 2022	BUY	$16.5 - $25.48 $657,607 - $1.02 Million	39,855 Added 22.93%	213,645 $3.79 Million
Q3 2021 Nov 10, 2021	BUY	$17.81 - $24.87 $1,264 - $1,765	71 Added 0.04%	173,790 $4 Million
Q2 2021 Aug 05, 2021	BUY	$22.19 - $31.55 $5,503 - $7,824	248 Added 0.14%	173,719 $4.04 Million
Q1 2021 May 14, 2021	BUY	$26.99 - $40.0 $4.49 Million - $6.65 Million	166,336 Added 2331.27%	173,471 $5.41 Million
Q4 2020 Feb 12, 2021	BUY	$36.35 - $45.25 $259,357 - $322,858	7,135 New	7,135 $284,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

Stay updated on American Century Companies Inc with notifications on news.